Great Lakes Advisors LLC lessened its stake in shares of Cencora, Inc. (NYSE:COR – Free Report) by 0.9% during the 4th quarter, Holdings Channel reports. The fund owned 339,378 shares of the company’s stock after selling 3,029 shares during the quarter. Great Lakes Advisors LLC’s holdings in Cencora were worth $114,626,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the stock. Nuveen LLC raised its holdings in shares of Cencora by 1.3% during the 4th quarter. Nuveen LLC now owns 804,582 shares of the company’s stock worth $271,748,000 after acquiring an additional 9,948 shares during the period. SmartHarvest Portfolios LLC purchased a new position in shares of Cencora during the 4th quarter worth $455,000. Stirlingshire Investments Inc. purchased a new position in shares of Cencora during the 4th quarter worth $276,000. Meeder Asset Management Inc. raised its holdings in shares of Cencora by 34,648.7% during the 4th quarter. Meeder Asset Management Inc. now owns 13,552 shares of the company’s stock worth $4,577,000 after acquiring an additional 13,513 shares during the period. Finally, Meeder Advisory Services Inc. raised its holdings in shares of Cencora by 13.6% during the 4th quarter. Meeder Advisory Services Inc. now owns 6,916 shares of the company’s stock worth $2,336,000 after acquiring an additional 826 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Analyst Ratings Changes
Several research analysts have recently commented on COR shares. Weiss Ratings lowered Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Citigroup reduced their price target on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. UBS Group raised their price objective on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley set a $342.00 price objective on Cencora in a research report on Friday, May 8th. Finally, William Blair began coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating for the company. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $374.00.
Cencora Stock Up 0.2%
Shares of NYSE:COR opened at $281.88 on Friday. The business has a 50-day moving average price of $289.95 and a 200 day moving average price of $327.96. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The company has a market capitalization of $54.84 billion, a price-to-earnings ratio of 21.62, a PEG ratio of 1.52 and a beta of 0.59. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.
Cencora (NYSE:COR – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.
Cencora Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is currently 18.40%.
Cencora declared that its board has authorized a stock repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.
Cencora Profile
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Stories
- Five stocks we like better than Cencora
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
